Transcriptome Sequencing Market (2025-2035)

The sharp drop in sequencing costs is a major factor boosting the transcriptome sequencing market. Since 2008, sequencing costs have decreased much more quickly than Moore's Law predicted. NHGRI has tracked a steady reduction in the cost per genome across its funded centers. Illumina's NovaSeq X Series aims for a $200 genome at list price on its 25B flow cell and can process over 20,000 genomes per year on NovaSeq X Plus. Meanwhile, Ultima Genomics introduced UG 100 Solaris in February 2025. This platform offers 10 to 12 billion reads per wafer, with prices as low as $0.24 per million reads (about $80 per genome at 30×) and the capacity for over 30,000 genomes per year. 

On the ultra-high-throughput side, Complete Genomics' DNBSEQ T20×2 claims it can process around 50,000 genomes per year and offers a path to reagent costs under $100 through dip immersion biochemistry and reagent reuse. Throughput has also increased, with Illumina reporting up to 16 Tb per run on NovaSeq X Plus (dual flow cell) and up to 26B single reads per flow cell. This allows for population-scale projects to be completed more quickly. Long-read platforms are also closing the price gap. PacBio Revio with SPRQ chemistry can report about 2,500 human genomes per year at just under $500 per genome. It also reduces DNA input to 500 ng while enhancing methylation calling for multiomic insights in every run. Together, these factors are speeding up transcriptome and genome programs from discovery to clinical application. 

Precision medicine is quickly becoming essential in modern healthcare, with transcriptome sequencing playing a vital role in this change. By examining gene expression patterns, doctors can better understand disease mechanisms and choose treatments tailored to individual patients. Large initiatives such as the NIH's All of Us Research Program have already enrolled over 633,000 participants and sequenced more than 414,000 whole genomes, highlighting the rapid progress in personalized medicine. 

Companion diagnostics are crucial to this shift. These tests help determine treatment options by matching patients with targeted therapies based on their molecular profiles. A significant milestone was reached in August 2024 when the FDA approved Illumina's TruSight Oncology Comprehensive (TSO) test. This panel can analyze over 500 genes, including RNA fusions like NTRK and RET, and acts as a companion diagnostic for treatments like VITRAKVI and RETEVMO. This illustrates the increasing importance of RNA sequencing in clinical oncology. Pharmaceutical companies are also incorporating companion diagnostics into their drug development processes. In 2024, QIAGEN expanded its partnership with AstraZeneca to create rapid diagnostic tools for chronic diseases using the QIAstat-Dx platform, which provides results during regular clinical visits.

Single-cell RNA sequencing is transforming research by allowing scientists to study individual cells rather than averaging signals across thousands. This capability is critical for understanding cancer, immune disorders, and neurological diseases, where cell-to-cell differences drive treatment outcomes. In February 2025, the Chan Zuckerberg Initiative launched the Billion Cells Project with 10x Genomics and Ultima Genomics, aiming to analyze over one billion cells to build advanced AI models for disease research. New platforms like Parse Biosciences' GigaLab, which can process up to 10 million cells in a single run and scale to 2.5 billion cells annually, and CS Genetics' SimpleCell kit, enabling same-day analysis of 96 samples, are making single-cell studies faster and more accessible.

Spatial transcriptomics is gaining momentum as well. Unlike traditional sequencing, it preserves tissue architecture, showing not only which genes are active but where they are active. This is crucial for mapping tumor microenvironments, brain regions, and developmental processes. Leading platforms such as 10x Genomics' Visium HD, launched in 2024, deliver whole-transcriptome spatial analysis at near single-cell resolution, while Bruker's CosMx and GeoMx systems expanded in 2025 to include whole-transcriptome panels and 1,000-plex protein assays, pushing the boundaries of multi-modal tissue profiling.

Artificial intelligence is changing how we analyze transcriptome data. It makes the process faster and provides deeper insights. AI-driven tools now support every part of the workflow, from experimental design and automation to understanding complex sequencing data. Deep learning models help researchers tackle challenges in single-cell and spatial transcriptomics. They address issues like sparse data and batch effects by combining multiple data types for richer insights. 

New developments are making analysis easier to access. In 2025, Nature Biotechnology featured CellWhisperer. This tool uses multimodal learning and natural language interfaces to allow scientists to query single-cell RNA sequencing data in a conversational way. This represents a significant step towards making data exploration more available to everyone. AI is also speeding up drug discovery by identifying biomarkers and predicting treatment responses. A notable example is the Illumina-NVIDIA partnership announced in May 2025. This collaboration combines Illumina's DRAGEN platform with NVIDIA's BioNeMo AI framework. It increases multiomics data processing speeds by 5 to 10 times, which greatly reduces time-to-insight for researchers and clinicians.